Production (Stage)
Nika Pharmaceuticals, Inc.
NIKA
$0.6495
-$0.0004-0.06%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -2.63% | 88.12% | 60.74% | 72.09% | -53.71% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -2.63% | 88.12% | 60.74% | 72.09% | -97.15% |
| Operating Income | 2.85% | -87.81% | -60.47% | -71.80% | 97.15% |
| Income Before Tax | 2.85% | -87.81% | -60.47% | -71.80% | 97.15% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 2.85% | -87.81% | -60.47% | -71.80% | 97.15% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2.85% | -87.81% | -60.47% | -71.80% | 97.15% |
| EBIT | 2.85% | -87.81% | -60.47% | -71.80% | 97.15% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 0.00% | -- | -- | -- | 97.67% |
| Normalized Basic EPS | -- | -- | -- | -- | 100.00% |
| EPS Diluted | 0.00% | -- | -- | -- | 97.67% |
| Normalized Diluted EPS | -- | -- | -- | -- | 100.00% |
| Average Basic Shares Outstanding | 16.84% | 12.55% | -0.71% | -0.92% | -1.15% |
| Average Diluted Shares Outstanding | 16.84% | 12.55% | -0.71% | -0.92% | -1.15% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |